| Anti-CD20 monoclonal antibodies in multiple sclerosis I Moreno Torres, A García-Merino Expert review of neurotherapeutics 17 (4), 359-371, 2017 | 50 | 2017 |
| Immunophenotype and transcriptome profile of patients with multiple sclerosis treated with fingolimod: Setting up a model for prediction of response in a 2-year translational study I Moreno-Torres, C González-García, M Marconi, A García-Grande, ... Frontiers in immunology 9, 1693, 2018 | 44 | 2018 |
| Mechanisms of action of cannabidiol in adoptively transferred experimental autoimmune encephalomyelitis C González-García, IM Torres, R García-Hernández, L Campos-Ruíz, ... Experimental neurology 298, 57-67, 2017 | 35 | 2017 |
| Risk and outcomes of COVID‐19 in patients with multiple sclerosis I Moreno‐Torres, V Meca Lallana, L Costa‐Frossard, C Oreja‐Guevara, ... European journal of neurology 28 (11), 3712-3721, 2021 | 34 | 2021 |
| SARS-CoV-2 infection in multiple sclerosis: results of the Spanish Neurology Society Registry G Arrambide, MÁ Llaneza-González, L Costa-Frossard França, ... Neurology: Neuroimmunology & Neuroinflammation 8 (5), e1024, 2021 | 30 | 2021 |
| Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population J Sabin, S Urtiaga, B Pilo, I Thuissard, V Galan, S Sainz de la Maza, ... Journal of Neurology 267, 2362-2371, 2020 | 26 | 2020 |
| Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis I Moreno Torres, AJ Sanchez, A Garcia-Merino Expert review of neurotherapeutics 14 (11), 1243-1250, 2014 | 25 | 2014 |
| EMCAM (Multiple Sclerosis Autonomous Community of Madrid) document for the management of patients with multiple sclerosis during the SARS-CoV-2 pandemic L Costa-Frossard, I Moreno-Torres, V Meca-Lallana, ... Revista de Neurologia 70 (9), 329-340, 2020 | 12 | 2020 |
| Documento EMCAM (Esclerosis Múltiple Comunidad Autónoma de Madrid) para el manejo de pacientes con esclerosis múltiple durante la pandemia de SARS-CoV-2 L Costa-Frossard, I Moreno-Torres, V Meca-Lallana, ... Rev. neurol.(Ed. impr.), 329-340, 2020 | 11 | 2020 |
| CHAPTER 1. Multiple Sclerosis: Epidemiology, Genetics, Symptoms, and Unmet Needs I Moreno Torres, J Sabin, A Garcia-Merino Emerging Drugs and Targets for Multiple Sclerosis 1, 1-32 DOI: 10.1039 …, 2019 | 11* | 2019 |
| En Representacion Del Grupo de Estudio de Enfermedades Desmielinizantes de la Comunidad Autonoma de Madrid E.[EMCAM (Multiple Sclerosis Autonomous Community of Madrid) document … L Costa-Frossard, I Moreno-Torres, V Meca-Lallana, ... Rev Neurol 70 (9), 329-40, 2020 | 5 | 2020 |
| COVID-19 in cladribine-treated patients with multiple sclerosis C Oreja-Guevara, V Meca-Lallana, L Brieva, E Fernandez-Diaz, ... Multiple Sclerosis Journal, 59-60, 2020 | 5 | 2020 |
| Efficacy and safety of fingolimod in routine clinical practice in patients with relapsing-remitting multiple sclerosis in Spain: an intermediate analysis of the MS NEXT study J Mallada-Frechin, V Meca-Lallana, F Barrero, ML Martinez-Gines, ... Revista de neurologia 67 (5), 157-167, 2018 | 4 | 2018 |
| Vaccination against SARS-CoV-2 in patients with multiple sclerosis JM García-Domínguez, I Moreno-Torres, J Fortún, LM Villar, ... Revista de Neurologia 72 (7), 250-260, 2021 | 3 | 2021 |
| Efectividad y seguridad del fingolimod en la práctica clínica habitual en pacientes con esclerosis múltiple remitente recurrente en España: análisis intermedio del estudio MS NEXT J Mallada-Frechin, V Meca-Lallana, F Barrero, ML Martinez-Gines, ... Rev. neurol.(Ed. impr.), 157-167, 2018 | 3 | 2018 |
| Vacunación frente al SARS-CoV2 en pacientes con esclerosis múltiple L Costa Frossard-França, JM García-Domínguez, I Moreno-Torres, ... Rev Neurol 72 (7), 250-260, 2021 | 2* | 2021 |
| Risk and outcomes of COVID-19 in patients with multiple sclerosis in Madrid Spain I Moreno-Torres, V Meca-Lallana, L Costa-Frossard, C Oreja-Guevara, ... Multiple Sclerosis Journal, 60-60, 2020 | 2 | 2020 |
| Dimethyl fumarate-related immune and transcriptional signature is associated with clinical response in multiple sclerosis-treated patients A Sánchez-Sanz, S García-Martín, J Sabín-Muñoz, I Moreno-Torres, ... Frontiers in Immunology 14, 1209923, 2023 | 1 | 2023 |
| PMS8 HIGH-COST MEDICATIONS IN 10 COUNTRIES: A CROSS-SECTIONAL COMPARATIVE STUDY O Canon, L Daza, J Gomez, I Moreno, C Castillo, J Rodriguez Value in Health 3 (13), A123, 2010 | 1 | 2010 |
| Response to Fingolimod in Multiple Sclerosis Patients Is Associated with a Differential Transcriptomic Regulation A Sánchez-Sanz, R Muñoz-Viana, J Sabín-Muñoz, I Moreno-Torres, ... International Journal of Molecular Sciences 25 (3), 1372, 2024 | | 2024 |
María Coral González GarcíaProfesora Universidad a Distancia de Madrid (UDIMA)Verified email at udima.es
